8 Bridge Group, LLC has acquired a majority stake in 340BIntel, LLC, marking the firm's strategic entry into the healthcare technology sector. The Birmingham, Alabama based company announced the investment as the first phase of a long-term initiative expected to exceed US$2 billion in revenue over the next decade. The move is designed to support software innovation that strengthens healthcare operations and improves financial sustainability for providers.
Strategic Rationale for the Investment
The investment reflects 8 Bridge Group's plan to diversify into high-growth technology businesses that serve critical industries. The firm's executive team has spent more than a decade assisting hospitals, health systems, and clinic networks with operational efficiency. By acquiring a majority stake in 340BIntel, 8 Bridge Group gains a specialized platform that addresses financial pressures in the 340B drug pricing program.
Understanding the 340B Program Landscape
The 340B drug pricing program enables eligible Covered Entities to purchase outpatient drugs at discounted prices, but compliance and optimization have become increasingly complex. Many hospitals and health systems struggle to capture all eligible savings under current administrative workflows. 340BIntel helps these organizations navigate rising financial pressures while maintaining regulatory compliance and operational stability.
Capabilities of the 340BIntel Platform
340BIntel's proprietary technology identifies and recovers previously unclaimed 340B savings across prescription capture, patient eligibility, referral patterns, and pharmacy network performance. The platform integrates alongside existing third-party administrators and internal 340B teams without requiring system replacements or workflow changes. This design enables Covered Entities to enhance program performance while preserving their existing operational models.
Leadership Perspectives on the Partnership
Heath Echols, Chief Operating Officer of 8 Bridge Group, emphasized that the technology recovers unclaimed 340B savings without disrupting existing workflows or operational models. Jaco van Niekerk, Chief Executive Officer of 8 Bridge Group, said the partnership aligns with a long-term vision to invest in software that strengthens healthcare organizations. Elton Wagnon, Chief Growth Officer of 8 Bridge Group, added that the mission is to help healthcare organizations recover every eligible dollar through the 340B program.
Growth Targets and Development Resources
8 Bridge Group brings financial backing and more than 100 developers to help expand 340BIntel's offering locally and nationally. 340BIntel is in the process of adding 120 nonprofit hospitals to its network by the fourth quarter of 2027. The company's shareholders and management expect this expansion to help nonprofit hospitals maximize eligible savings and better serve their communities.
Commitment to Community Healthcare
The partnership aims to support transparency, accountability, and the healthcare safety net while helping providers strengthen care for low-income and uninsured patients. Recovered 340B savings can be reinvested into patient care and community services, expanding access to critical health resources. This focus aligns with the broader mission of nonprofit hospitals that rely on the 340B program to serve vulnerable populations.
About 8 Bridge Group
8 Bridge Group is a diversified investment company focused on identifying and accelerating high-growth technology businesses across strategic industries through long-term investments and operational expertise. The firm's entry into the healthcare technology sector reflects its broader strategy of supporting software applications in critical markets. This investment establishes a foundation for additional growth opportunities in the healthcare market.
8 Bridge Group's acquisition of a majority stake in 340BIntel signals a deliberate expansion into healthtech and a long-term commitment to operational efficiency for healthcare providers. The partnership combines specialized technology, development capacity, and financial resources to help Covered Entities navigate the evolving 340B landscape. Financial terms of the transaction were not disclosed, but the initiative's scale and growth targets indicate significant ambition in the healthcare technology market.